Mahase E. COVID-19: Pfizer reports 100% vaccine efficacy in children aged 12 to 15. BMJ. 2021;373(n881):n881. doi:10.1136/bmj.n881PubMedGoogle Scholar 2. Heuerman E. Covid vaccine hesitancy drops among all Americans, new survey shows. Accessed June 5, 2021.https://khn...
Objective To determine the safety and efficacy of CCP compared with placebo in hospitalized patients with COVID-19 receiving noninvasive supplemental oxygen. Design, Setting, and Participants CONTAIN COVID-19, a randomized, double-blind, placebo-controlled trial of CCP in hospitalized adults with CO...
COVID-19 vaccination and allergy riskThose who had received the vaccine had a 44% higher risk of allergy (with one dose). This was reduced by 20% after two doses of the vaccine. The two-dose cohort had comparable allergy risk as the controls, both overall and for the various allergy ...
2. However, data related to the inactivated-virus vaccine (CoronaVac) of efficacy and effectiveness (VE) against the SARS-CoV-2 B.1.1.529 (Omicron) variant are lacking for children aged 6–11 years.
An EUA was issued for baricitinib on November 19, 2020 for use, in combination with remdesivir8, and for casirivimab and imdevimab on November 219. On December 11, 2020 the first vaccine (BNT-162b2 SARS-CoV-2 vaccine) was granted an EUA by the FDA and the same was accepted for a...
The vaccine efficacy information is presented in Table 8. Table 8: Vaccine Efficacy – First COVID-19 Occurrence From 7 Days After Dose 2, by Age Subgroup – Participants Without Evidence of Infection and Participants With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Evalu...
Recently, several studies have reported the effectiveness of novel COVID-19 vaccines. The efficacy of the BNT162b2 mRNA vaccine has been reported to be 95% (Polack et al., 2020), that of the mRNA-1273 vaccine is 94.1% (Baden et al., 2021), that of the Gam-COVID-Vac (Sputnik V)...
Among participants (n = 3502), 47% did not receive influenza vaccine in the prior 12 months and 53% had; 25.5% of non-vaccinators and 91.9% of vaccinators intended future vaccination. For non-vaccinators, odds of intending vaccination was associated with race/ethnicity (Hispanics were ...
Based on their response, respondents were categorized into 1 of 3 vaccine-intention groups (coded as 3 dummy variables): Acceptant: Getting vaccinated as soon as possible responses Hesitant: Continuing to wait for more safety or efficacy data, or “unsure” responses Resistant: Definitely not ...
They must pass rigorous and predetermined efficacy and safety metrics prior to licensure. Additionally, postmarketing safety surveillance is essential to detect rare or severe vaccine-associated adverse events, particularly because of the large numbers of individuals exposed. A primary method for post...